Immune globulin - Biotest Pharmaceuticals

Drug Profile

Immune globulin - Biotest Pharmaceuticals

Alternative Names: BT-595; Human normal immunoglobulin - Biotest; Pentaglobin

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biotest Pharmaceuticals
  • Developer Biotest Pharmaceuticals; RWTH Aachen University
  • Class Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Immune thrombocytopenic purpura; Immunodeficiency disorders
  • Phase II Sepsis; Septic shock

Most Recent Events

  • 02 Oct 2017 Phase-II clinical trials in Sepsis (In adults, In the elderly) in Germany (IV)
  • 02 Oct 2017 Phase-II clinical trials in Septic shock (In adults, In the elderly) in Germany (IV)
  • 01 Nov 2016 Phase-III clinical trials in Immune thrombocytopenic purpura (In adults, In the elderly) in Germany, Hungary, Spain, Czech Republic, Bulgaria (IV) (NCT02859909) (EudraCT2015-003653-17)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top